Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03699579
NCT03699579
Completed
Not Applicable

Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan

Ipsen2 sites in 1 country28 target enrollmentFebruary 22, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRenal Cell Carcinoma MetastaticRenal Cell Carcinoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Cell Carcinoma Metastatic
Sponsor
Ipsen
Enrollment
28
Locations
2
Primary Endpoint
Medication usage
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

Registry
clinicaltrials.gov
Start Date
February 22, 2019
End Date
June 23, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ipsen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with confirmed diagnosis of clear-cell renal cell carcinoma
  • •Patients with evidence of metastatic disease
  • •Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
  • •Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease

Exclusion Criteria

  • •Patients enrolled in any clinical trial involving anti-cancer therapy
  • •Pregnant woman

Outcomes

Primary Outcomes

Medication usage

Time Frame: From start point for 2.5 months

Treatment's duration

Time Frame: From start point for 2.5 months

Secondary Outcomes

  • Cost of medication used(From start point for 2.5 months)
  • Costs of adverse event management(From start point for 2.5 months)
  • Frequency of health resource usage(From start point for 2.5 months)
  • Cost of health resource usage(From start point for 2.5 months)

Study Sites (2)

Loading locations...

Similar Trials

Terminated
Not Applicable
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesBreast Cancer
NCT04396626Pfizer975
Completed
Not Applicable
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In ColombiaAtrial Fibrillation
NCT04234698Pfizer2,076
Completed
Not Applicable
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.Metastatic Breast Cancer
NCT04671615Pfizer559
Completed
Not Applicable
Oxycodone User Registry (OUR)Pain
NCT00978328Ortho-McNeil Janssen Scientific Affairs, LLC827
Withdrawn
Not Applicable
Characteristics of Patients With COVID-19 in Meta State, ColombiaCOVIDSARS-CoV 2SARS PneumoniaSARS (Disease)SARS (Severe Acute Respiratory Syndrome)
NCT04456426Hospital Departamental de Villavicencio